MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial

Merit Medical Systems, Inc. (MMSI) announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday. The WAVE trial was designed to assess the efficacy and safety of the WRAPSODY device.The WRAPSODY Cell-Impermeable Endoprosthesis is currently not approved or available for commercial distribution in the United States. It may also not be approved or available for sale or use in other countries. However, the ...